TSRO up +2.55% percent right now. $TSRO High is at 29.20

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 3:21 PM

TSRO up +2.55% percent right now. $TSRO High is at 29.20 and the Low 28.20 with current volume of 114,938.

Recent News posted below.

TSRO Tesaro Inc Recent Headline News

TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 1:31AM CST

TSRO: 28.67 (+0.39)

Tesaro beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:04AM CST
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a third-quarter loss of $36.2 million.
TSRO: 28.67 (+0.39)

Tesaro beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:07PM CST

TSRO: 28.67 (+0.39)

TESARO Announces Third-Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 05, 3:36PM CST
-- Oral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDA
TSRO: 28.67 (+0.39)

Tesaro reports November 5
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:34PM CDT

TSRO: 28.67 (+0.39)

Tesaro to Announce Third-Quarter 2014 Financial Results on November 5, 2014
GlobeNewswire - Wed Oct 22, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its third-quarter 2014 financial results on Wednesday, November 5, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 5, 2014 to discuss the Company's results in greater detail.
TSRO: 28.67 (+0.39)

TESARO Announces Closing of $201.25 Million Public Offering of 3.00% Convertible Senior Notes Due 2021, Including Full Exercise of the Underwriters' Option to Purchase Additional Notes
GlobeNewswire - Mon Sep 29, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of $201.25 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes"

, including the notes issued pursuant to the full exercise of the underwriters' option to purchase up to $26.25 million aggregate principal amount of additional notes on the same terms and conditions. As a result, aggregate net proceeds to TESARO, after deducting the underwriting discount and estimated offering expenses payable by TESARO, will be approximately $194.71 million.
TSRO: 28.67 (+0.39), DB: 30.12 (+0.12)

Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:54AM CDT
Make sure to keep a close watch on Tesaro in the near future, and especially on earnings estimates following the recent slump.
TSRO: 28.67 (+0.39)

TESARO Announces Pricing of $175 Million of 3.00% Convertible Senior Notes Due 2021
GlobeNewswire - Tue Sep 23, 9:40PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes"

in an underwritten public offering. The size of the offering was increased from the previously announced aggregate principal amount of $165 million. TESARO has granted the underwriters a 30-day option to purchase up to $26.25 million aggregate principal amount of additional notes on the same terms and conditions to cover over-allotments. The offering is expected to close on or about September 29, 2014, subject to customary closing conditions.
TSRO: 28.67 (+0.39), DB: 30.12 (+0.12)

Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UBNT: 28.58 (-0.62), TSRO: 28.67 (+0.39), WATT: 9.48 (-0.21), MLAB: 81.34 (-2.04), NVC.TO: 6.90 (+0.50), NVCN: 6.08 (+0.28), PBSK: 14.79 (-0.11)

TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021
GlobeNewswire - Mon Sep 22, 3:46PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today that, subject to market and other conditions, it intends to offer $165 million aggregate principal amount of convertible senior notes due 2021 (the "notes"

in an underwritten public offering. TESARO also expects to grant the underwriters a 30-day option to purchase up to $24.75 million aggregate principal amount of additional notes on the same terms and conditions to cover over-allotments. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TSRO: 28.67 (+0.39), DB: 30.12 (+0.12)

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
ENDP: 67.87 (-1.00), TSRO: 28.67 (+0.39), OPK: 8.51 (-0.12), MRK: 59.26 (+0.45)

OPKO Licensee TESARO Submits New Drug Application for Rolapitant
Business Wire - Mon Sep 08, 11:20AM CDT
OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
TSRO: 28.67 (+0.39), OPK: 8.51 (-0.12)

TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration
GlobeNewswire - Mon Sep 08, 7:06AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for oral rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).
TSRO: 28.67 (+0.39)

TESARO Announces Participation at Several Upcoming Investor Conferences
GlobeNewswire - Thu Aug 21, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, Executive Vice President and CFO of TESARO, will participate in several upcoming investor conferences during the month of September, including:
TSRO: 28.67 (+0.39)

TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
ENDP: 67.87 (-1.00), TSRO: 28.67 (+0.39), SLXP: 97.77 (+3.90), ENTA: 43.11 (-1.03)

TESARO Appoints Mary Lynne Hedley, Ph.D., as Chief Operating Officer
GlobeNewswire - Thu Jul 24, 3:09PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
TSRO: 28.67 (+0.39)

TESARO Announces Second-Quarter 2014 Operating Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
-- Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDA
TSRO: 28.67 (+0.39)

Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
BIIB: 323.92 (-3.95), MYGN: 32.18 (-0.62), TSRO: 28.67 (+0.39)

TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014
GlobeNewswire - Thu Jul 10, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on July 24, 2014 to discuss the Company's results in greater detail.
TSRO: 28.67 (+0.39)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

TORRAS Stands Tall with iPhone 18 Pro Cases

By Riley Hayes Updated Oct 24, 2026 Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...